Leerink Partners Serves as Exclusive Financial Advisor and Placement Agent to Universal DX on its $70 Million Series B Financing and Strategic Collaboration with Quest Diagnostics
Leerink Partners Serves as Exclusive Financial Advisor to Freeline Therapeutics (Nasdaq: FRLN) on its Going-Private Transaction with Syncona (LON: SYNC)